U.S. Food & Drug Administration approves Accord BioPharma’s HERCESSI, a biosimilar to Herceptin
The U.S. Food and Drug Administration (FDA) has approved Accord BioPharma’s HERCESSI (trastuzumab-strf), a biosimilar to Herceptin (trastuzumab), to treat HER2-overexpressing breast and gastric or gastroesophageal junction adenocarcinoma. “The approval of …